Role of Tegoprazan in Helicobacter pylori Eradication Therapy
Abstract
Potassium-competitive acid blockers (P-CABs) have a stronger acid-suppressing effect than proton pump inhibitors (PPI), showing comparable or superior effects in various diseases in which PPIs were used. Many studies have reported the role of P-CAB in Helicobacter pylori eradication. Vonoprazan is a novel P-CAB approved and used for H. pylori eradication in Japan. In recent years, several studies have compared the eradication rates of vonoprazanand PPI-containing triple therapies across centers in Japan. The superior efficacy of vonoprazan-containing eradication treatment has been demonstrated in recent meta-analyses and is mainly explained by the rapid and potent suppression of gastric acid secretion. Tegoprazan is a P-CAB developed in Korea, and, similar to vonoprazan, it showed a stronger and faster effect than PPIs. Therefore, the rapid and potent anti-acid efficacy of tegoprazan is considered optimal for H. pylori eradication therapy. In this issue of Gut and Liver, Choi et al. report the efficacy of tegoprazan as a part of first-line triple therapy for H. pylori eradication. A randomized, double-blind, controlled, multicenter study was performed to evaluate whether a 50-mg tegoprazan-based triple therapy was non-inferior to a 30-mg lansoprazole-based triple therapy. A total of 350 H. pylori-positive patients were randomly allocated to either the tegoprazan or lansoprazole groups. The H. pylori eradication rates in the tegoprazan and lansoprazole groups were 62.86%…
How strong is the evidence?
Evidence Hub reads this as a randomized trial. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years — Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2018
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study
- Occupation and risk of severe COVID-19: prospective cohort study of 120,075 UK Biobank participants
- Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study
- Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.